E. Andres Rivera-Munoz

E. Andres Rivera-Munoz

Auto-generated profile, based on publicly available information

E. Andres Rivera-Munoz

Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2018 in Human Mutation
Verified
Journal Article
Closed access
PDF file
EREdgar A. Rivera‐Muñoz
Edgar A. Rivera‐Muñoz
LMLaura Vogel Milko
Laura Vogel Milko
SHSteven Harrison
Steven Harrison
DADanielle R. Azzariti
Danielle R. Azzariti
CKC. Lisa Kurtz
C. Lisa Kurtz
JBJonathan S. Berg
Jonathan S. Berg


6 September 2025 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
ERE. Andres Rivera-Munoz
E. Andres Rivera-Munoz
XZXiaonan E. Zhao
Xiaonan E. Zhao
JRJill A. Rosenfeld
Jill A. Rosenfeld
PLPamela N. Luna
Pamela N. Luna
CSChad A. Shaw
Chad A. Shaw
DSDaryl A. Scott
Daryl A. Scott
Congenital Anomalies of Kidney and Urinary Tract (CAKUT) can occur in isolation or in conjunction with one or more non-CAKUT associated congenital anomalies or neurodevelopmental disorders (CAKUT+). A molecular cause is not identified in most individuals with CAKUT+. This is due, in part, to uncertainty regarding the efficacy of genetic testing and an incomplete understanding of the genes that cause CAKUT+. Here, we use data from 515 individuals with CAKUT+ ( n  = 500) or isolated CAKUT ( n  = 15) to determine the efficacy of clinical exome sequencing (cES) and to identify new phenotype expansions that involve CAKUT. We determined that cES established a molecular diagnosis in 27.4% (141/515) of individuals in this cohort. No statistically significant difference in efficacy was seen with regards to age, sex, CAKUT phenotype, or associated organ system abnormality. Only 3.5% (5/144) to 14.6% (21/144) of the individual diagnoses made in our cohort could have been identified using one of four clinically available CAKUT gene panels. We then used a machine-learning approach to confirm that PHIP is a CAKUT gene and to implicate ADNP and SETD5 genes associated with an increased risk of CAKUT. These findings lead us to conclude that cES should be considered in individuals with CAKUT+ for whom a molecular diagnosis has not been identified, that cES has the potential to identify many diagnoses in individuals with CAKUT+ that would be missed using a CAKUT gene panel, and that individuals with ADNP -, PHIP -, and SETD5 -related disorders may present with CAKUT phenotypes.

9 February 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JCJessica Xiao-Ling Chong
Jessica Xiao-Ling Chong
SBSeth I. Berger
Seth I. Berger
SBSamantha Baxter
Samantha Baxter
ESErica Smith
Erica Smith
CXChangrui Xiao
Changrui Xiao
HHeidi Rehm
Heidi Rehm
Since the first novel gene discovery for a Mendelian condition was made via exome sequencing (ES), the rapid increase in the number of genes known to underlie Mendelian conditions coupled with the adoption of exome (and more recently, genome) sequencing by diagnostic testing labs has changed the landscape of genomic testing for rare disease. Specifically, many individuals suspected to have a Mendelian condition are now routinely offered clinical ES. This commonly results in a precise genetic diagnosis but frequently overlooks the identification of novel candidate genes. Such candidates are also less likely to be identified in the absence of large-scale gene discovery research programs. Accordingly, clinical laboratories have both the opportunity, and some might argue a responsibility, to contribute to novel gene discovery which should in turn increase the diagnostic yield for many conditions. However, clinical diagnostic laboratories must necessarily balance priorities for throughput, turnaround time, cost efficiency, clinician preferences, and regulatory constraints, and often do not have the infrastructure or resources to effectively participate in either clinical translational or basic genome science research efforts. For these and other reasons, many laboratories have historically refrained from broadly sharing potentially pathogenic variants in novel genes via networks like Matchmaker Exchange, much less reporting such results to ordering providers. Efforts to report such results are further complicated by a lack of guidelines for clinical reporting and interpretation of variants in novel candidate genes. Nevertheless, there are myriad benefits for many stakeholders, including patients/families, clinicians, researchers, if clinical laboratories systematically and routinely identify, share, and report novel candidate genes. To facilitate this change in practice, we developed criteria for triaging, sharing, and reporting novel candidate genes that are most likely to be promptly validated as underlying a Mendelian condition and translated to use in clinical settings.

19 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
MMMullai Murugan
Mullai Murugan
BYBo Yuan
Bo Yuan
JSJoshi Stephen
Joshi Stephen
CGCharul Gijavanekar
Charul Gijavanekar
SXShengfeng Xu
Shengfeng Xu
EVEric Venner
Eric Venner
BACKGROUND: Genetic variant curation, an important step in the implementation of Genomic Medicine, requires literature-guided comparison of variant prevalence in affected individuals versus healthy controls. This evidence is categorized as the PS4 evidence code by the AMP/ACMG variant interpretation guidelines and its manual extraction is a major bottleneck in clinical variant curation. This study aimed to evaluate whether reasoning-capable large language models (LLMs) can support guideline-constrained PS4 evidence extraction from literature. METHODS: We benchmarked five LLMs for publication-level variant detection and PS4-eligible proband counting under ACMG/AMP and ClinGen Variant Curation Expert Panel (VCEP) guidance using an expert-curated truth-set. We assembled an expert-curated truth-set of 281 publication-variant pairs from 275 peer-reviewed publications (58 genes and 128 variants). Five LLMs spanning frontier-scale, reasoning-optimized, and efficiency-oriented classes (Gemini 2.5 Pro, GPT-5, o3, o4-mini, and Claude Sonnet 4) were evaluated against this truth-set using identical inputs, a unified prompt template, and a schema-constrained JSON output format on two tasks: (1) determining whether a prespecified variant was correctly identified and (2) counting independent PS4-eligible probands under applicable guidance. Primary outcomes were Task 1 accuracy and Task 2 exact-count concordance (model PS4 count equals truth-set count). We also assessed prompt sensitivity, error modes, and output variability across models. RESULTS: Models were able to detect the presence of a variant in a publication with high accuracy (93.6-97.9%). For PS4 case counting, exact-count concordance was highest for Gemini 2.5 Pro (91.1%) and GPT-5 (90.0%), followed by o3 (86.5%), o4-mini (79.4%), and Claude Sonnet 4 (73.0%). Most counting errors resulted from an inability of a model to correctly apply guidelines, including evaluating phenotype and family structure. Prompt refinements improved concordance for most models but reduced performance for Claude Sonnet 4, indicating model specific prompting may be warranted. CONCLUSIONS: Reasoning-capable LLMs can support automation of guideline-based PS4 evidence extraction, achieving high concordance with expert curation, but performance is model- and prompt-dependent and failures concentrate in applying guidelines. Our findings support a hybrid workflow for clinical use in which LLM outputs accelerate evidence extraction with expert escalation.